<DOC>
	<DOCNO>NCT01394510</DOCNO>
	<brief_summary>Insulin secrete cell pancreas call beta-cells . Beta-cell dysfunction critical feature type 2 diabetes ( T2DM ) . High glucose level exacerbate beta-cell dysfunction oxidative stress propose major mediator `` glucotoxic '' effect . High glucose level also show contribute vascular dysfunction inflammation adverse response decrease use antioxidant . The hypothesis antioxidant improve beta-cell function individual elevate glucose level decrease oxidative stress . In study investigator specifically test whether antioxidant N-acetylcysteine ( NAC ) improve beta-cell function individual type 2 diabetes decrease oxidative stress . This study dose find study determine tolerability 600 mg versus 1200 mg twice day NAC effect beta-cell function , glucose tolerance oxidative stress marker person type 2 diabetes .</brief_summary>
	<brief_title>Effect Anti-oxidant N-acetylcysteine Beta-cell Function Type 2 Diabetes</brief_title>
	<detailed_description>Beta-cell dysfunction critical feature type 2 diabetes ( T2DM ) . High glucose level exacerbate beta-cell dysfunction oxidative stress propose major mediator `` glucotoxic '' effect . High glucose level also show contribute vascular dysfunction inflammation adverse response decrease use antioxidant . The hypothesis antioxidant improve beta-cell function individual elevate glucose level decrease oxidative stress . In study investigator specifically test whether antioxidant N-acetylcysteine ( NAC ) improve beta-cell function individual type 2 diabetes decrease oxidative stress . This initial study dose find study determine tolerability 600 mg versus 1200 mg twice day NAC effect NAC treatment beta-cell function , glucose tolerance oxidative stress marker person type 2 diabetes . Study procedure include fast urine sample performance 2 hour 75 gram oral glucose tolerance test baseline , 2 week 600 mg twice daily NAC 2 week 1200 mg NAC twice day .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>Type 2 diabetes Pregnant lactate female Uncontrolled diabetes mellitus severe hyperglycemia ( hemoglobin A1C ≥ 9 % ) Patients diabetes mellitus take insulin glucoselowering agent metformin Chronic oral parenteral corticosteroid treatment ( &gt; 7 consecutive day treatment ) within 8 week prior screen Use human immunodeficiency virus ( HIV ) protease inhibitor niacin Chronic inflammatory disease use antiinflammatory drug . Thyroid abnormality ( thyroidstimulating hormone [ TSH ] &lt; 0.5 &gt; 5 µU/ml ) Creatinine &gt; 1.5 men &gt; 1.3 mg/dl woman History dysphagia , gastroparesis , gastric ulcer , malabsorption , swallow disorder intestinal motility disorder Gastroesophageal reflux disease ( heartburn ) require treatment . Active cancer Clinical hepatic disease alanine aminotransferase ( ALT ) great ≥ 1.5 time upper limit normal within 60 day precede first dose study drug Weight loss &gt; 5 % body weight within last 6 month , start intensive exercise program within 4 week study initiation Smoke use tobacco Excessive alcohol consumption ( &gt; 2 drink day ) Use investigational drug last 30 day Anemia ( hematocrit &lt; 33 % ) , donation one unit ( 500 ml ) blood , significant blood loss equal least one unit blood within past 2 week blood transfusion within 8 week prior screen Employment research center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>insulin secretion</keyword>
	<keyword>beta-cell function</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>type 2 diabetes</keyword>
</DOC>